Sitagliptin increases CXCL10 expression by inhibiting dipeptidyl peptidase IV (DPPIV) and regulates lymphocyte transport to hepatocellular carcinoma (HCC) to promote regression (NCT02650427). The gene discussed is DPP4; the disease is hepatocellular carcinoma.